Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference
SOURCE Nuvalent, Inc.CAMBRIDGE, Mass, Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m. ET in NYC.
馬薩諸塞州劍橋，2024年11月26日 /美通社/ -- 努瓦倫特有限公司。 （納斯達克：NUVL），一家專注於爲癌症中已臨床證實的激酶靶點創建精準靶向療法的臨床階段生物製藥公司，今天宣佈，首席執行官詹姆斯·波特博士和首席財務官亞歷山德拉·巴爾康將於2024年12月3日星期二下午3:30，在紐約市參加派傑投資第36屆年度醫療保健大會期間舉行點燃法國壁爐談話。
A live webcast will be available in the Investors section of the company's website at , and archived for 30 days following the presentation.
公司網站的投資者部分將提供現場網絡廣播，地址爲 ，並在演示結束後存檔30天。
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
關於Nuvalent
Nuvalent, Inc.（納斯達克: NUVL）是一家專注於爲癌症患者創建精確靶向治療方案的臨床階段生物製藥公司，旨在克服已確認的激酶靶點現有治療方案的侷限性。憑藉在化學和基於構象的藥物設計方面的深厚專業知識，我們開發創新的小分子，有可能克服抵抗、減少不良事件、治療腦轉移，並獲得更持久的療效。Nuvalent正在推進一個龐大的管線，包括ROS1陽性、ALK陽性和HER2變異非小細胞肺癌的研究階段和多個發現階段的研究項目。
SOURCE Nuvalent, Inc.
資料來源: Nuvalent，Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
